EADV 2026 视频特辑｜史玉玲教授：CLEAR-2 亚组分析：IL-23抑制剂疗效稳定，不受体重与 BMI 影响

作为CLEAR-1和CLEAR-2的牵头研究者，史玉玲教授在 EADV 2026 大会汇报了 CLEAR-2 的亚组结果。研究按中国标准（BMI≥24 kg/m² 为超重、≥28 kg/m² 为肥胖）将中重度银屑病患者分为正常、超重与肥胖三组，结果显示 IL-23p19 抑制剂匹康奇拜单抗在三组人群中的疗效一致，提示其疗效稳定、不受体重或 BMI 影响；对于高体重或肥胖患者，IL-23 阻断剂因对疗效影响较小，可成为可选的治疗方案。

As the lead investigator of the CLEAR-1 and CLEAR-2 trials, Professor Shi Yuling presented the subgroup analysis results of the CLEAR-2 study at the EADV 2026 Congress.

In this trial, patients with moderate-to-severe psoriasis were stratified into three groups — normal weight, overweight, and obese — in accordance with Chinese criteria (overweight defined as BMI ≥ 24 kg/m², and obesity as BMI ≥ 28 kg/m²).

The results demonstrated consistent efficacy of the IL-23p19 inhibitor picankibart across all three groups, indicating that its therapeutic effect is stable and independent of body weight or BMI. For patients with higher body weight or obesity, IL-23 blockers represent a viable treatment option, as body weight exerts minimal impact on their therapeutic performance.